Promising Insights on Trisilanol i-Octyl POSS for Lung Injury Management

Liquid trisilanol i-octyl POSS produced rapid, durable control of bleeding and air leak in non-compressible pulmonary injuries in a preclinical swine lung-wound series.

In a controlled evaluation, investigators created standardized parenchymal lung incisions and applied a 1.5 mL bolus of the visco-liquid hemostat directly to wounds to test hemostasis and pneumostasis. The series included ten wounds treated with the agent trisilanol i-octyl POSS, with endpoints of clot formation and airtight sealing observed over a 10‑minute period. The model was open thoracotomy in swine to permit direct application and observation.

POSS achieved hemostasis in 8 of 10 lung wounds and produced rapid, durable sealing in the treated lesions in the swine model. The investigators reported faster time-to-hemostasis with POSS than with gauze and compression.

Pneumostasis was consistently achieved after POSS application and verified under positive-pressure inflation without subsequent rebleeding. These high initial clot rates and sustained seals represent a meaningful improvement over typical compressive measures in similar models.

No significant acute safety signals were observed: investigators reported acceptable local tolerability and no evidence of treatment-associated physiologic instability during the observation window. The visco-liquid interface appears to promote clot formation while conforming to irregular parenchymal geometry to create a pneumostatic seal without applied compression. Overall, acute safety findings in this preclinical context support further controlled testing.